```html

Johnson Disease (Lichen Planus Pemphigoides) – A Comprehensive Guide

Overview

Johnson disease, also known as lichen planus pemphigoides (LPP), is a rare, chronic autoimmune blistering disorder that displays features of both lichen planus (LP) and bullous pemphigoid (BP). The condition is characterized by violaceous, flat‑topped papules that later develop tense subepidermal blisters on previously affected skin.

Who it affects: LPP most commonly appears in adults between 40 and 70 years of age, with a slight male predominance (≈ 55 % of cases). However, it has been reported in children and adolescents, particularly when triggered by certain medications or infections.

Prevalence: Because LPP is rare, exact epidemiologic data are limited. Estimates suggest an incidence of < 1 per 100,000 persons per year, accounting for < 0.5 % of all autoimmune blistering diseases worldwide (Mayo Clinic, 2022). The condition may be under‑diagnosed due to its overlap with classic LP or BP.

Symptoms

The clinical picture evolves in two stages: an initial lichen planus phase followed by a blistering phase. The most common manifestations are:

• Violaceous, flat‑topped papules – often on the wrists, forearms, trunk, and lower legs. Lesions are shiny, may have fine white lines (Wickham’s striae), and can be intensely pruritic.
• Tense bullae – fluid‑filled blisters that arise on top of or adjacent to existing LP lesions. They are usually larger (5‑15 mm) and resistant to rupture.
• Koebner phenomenon – new lesions develop at sites of trauma such as scratching or pressure.
• Oral mucosal involvement – white, lace‑like plaques (reticular LP) or erosions; less common than in pure oral LP (≈ 20 % of LPP patients).
• Genital involvement – painful erosions or ulcerations, especially in men.
• Pruritus (itching) – often severe, leading to secondary excoriations.
• Burning or stinging sensation – may precede blister formation.
• Negative Nikolsky sign – skin does not shear off when stretched, distinguishing LPP from pemphigus.

Systemic symptoms such as fever, malaise, or joint pain are uncommon but may appear if extensive skin involvement triggers an inflammatory response.

Causes and Risk Factors

Underlying Mechanism

LPP is an autoimmune disorder in which the immune system produces antibodies that target structural proteins at the dermo‑epidermal junction, notably the BP180 (type XVII collagen) and, to a lesser extent, BP230. This immune attack leads to separation of the epidermis from the dermis, resulting in blisters. Simultaneously, a T‑cell–mediated response produces the classic lichen planus lesions.

Identified Triggers

• Medications – diuretics (e.g., furosemide), antihypertensives (ACE inhibitors), non‑steroidal anti‑inflammatory drugs (NSAIDs), and certain antibiotics have been implicated in case reports.
• Infections – hepatitis C virus (HCV) and human papillomavirus (HPV) have been associated with classic LP, and occasional reports link them to LPP.
• Physical trauma – rubbing, scratching, or surgical procedures may precipitate the Koebner phenomenon.
• Other autoimmune diseases – patients with thyroid disease, vitiligo, or rheumatoid arthritis appear to have a modestly increased risk.

Risk Factors

• Age > 40 years
• Male sex (slightly higher prevalence)
• History of lichen planus or other autoimmune skin diseases
• Exposure to known trigger medications
• Chronic hepatitis C infection

Diagnosis

Accurate diagnosis requires a combination of clinical assessment, histopathology, and immunopathologic testing.

Clinical Examination

• Identification of classic LP papules with overlying tense bullae.
• Distribution pattern (symmetric, often on extensors).
• Evaluation for mucosal lesions.

Skin Biopsy

1. Hematoxylin‑eosin (H&E) sample – taken from a fresh blister edge. Shows subepidermal cleft with eosinophil‑rich infiltrate and a lichenoid (band‑like) lymphocytic infiltrate at the dermal‑epidermal junction.
2. Direct immunofluorescence (DIF) – performed on perilesional skin. Reveals linear deposition of IgG and/or C3 along the basement membrane zone, a hallmark of pemphigoid disease. The presence of a lichenoid infiltrate helps differentiate LPP from pure BP.

Serologic Tests

• ELISA for BP180/BP230 antibodies – positive in ~70 % of LPP patients, often with higher titers than in isolated LP.
• Hepatitis C screening – recommended because HCV is linked to LP and may influence treatment decisions.

Other Investigations

• Complete blood count (CBC) and basic metabolic panel – baseline before systemic therapy.
• Pregnancy test for women of child‑bearing age before initiating teratogenic drugs (e.g., methotrexate).

Treatment Options

Treatment aims to control inflammation, stop blister formation, and reduce pruritus while minimizing side effects. Therapy is individualized based on disease severity, extent, and patient comorbidities.

First‑Line (Mild‑to‑Moderate Disease)

• High‑potency topical corticosteroids (e.g., clobetasol propionate 0.05 % ointment) applied twice daily to active lesions for 2–4 weeks, then tapered.
• Topical calcineurin inhibitors (tacrolimus 0.1 % ointment) for areas where steroids are contraindicated (face, intertriginous zones).
• Antihistamines (cetirizine, diphenhydramine) for pruritus relief.

Systemic Therapy (Moderate‑to‑Severe Disease)

1. Oral corticosteroids – Prednisone 0.5–1 mg/kg/day, tapered over 6–8 weeks. Effective for rapid control but long‑term use limited by side effects.
2. Immunosuppressants
   • Azathioprine 1.5–2 mg/kg/day
   • Mycophenolate mofetil 1–2 g/day divided BID
   Used as steroid‑sparing agents; monitor CBC and liver function.
3. Dapsone – 50–100 mg daily, especially helpful when eosinophilia is prominent. Requires G6PD testing before initiation.
4. Biologic agents
   • Rituximab (anti‑CD20) – 1 g IV on day 1 and day 15; shows remission in refractory cases (reported 70 % success in case series, JAMA Dermatology 2021).
   • Dupilumab – IL‑4Rα antagonist; emerging evidence suggests benefit for pruritic bullous diseases.

Procedural Options

• Intralesional corticosteroid injections – triamcinolone acetonide 10 mg/mL into persistent papules.
• Phototherapy – narrow‑band UVB or PUVA can improve LP lesions but may exacerbate blistering; use with caution.

Supportive & Lifestyle Measures

• Gentle skin care: use fragrance‑free emollients twice daily.
• Avoid scratching; keep fingernails trimmed.
• Wear loose, cotton clothing to reduce friction.
• Stay hydrated and maintain a balanced diet rich in antioxidants.

Living with Johnson Disease (Lichen Planus Pemphigoides)

Daily Skin Care

• Apply a thick, hypoallergenic moisturizer within 3 minutes of bathing to lock in moisture.
• Use lukewarm water instead of hot showers; limit bathing time to ≤ 10 minutes.
• Pat skin dry—do not rub.

Managing Itch

• Take oral antihistamines at night to break the itch‑scratch cycle.
• Apply topical menthol or camphor creams (avoid if skin is broken).
• Practice stress‑reduction techniques (mindfulness, yoga) as stress can worsen autoimmune activity.

Medication Adherence

• Maintain a medication diary; set alarms for doses.
• Schedule regular lab monitoring (CBC, liver enzymes, renal function) as recommended by your physician.

Psychosocial Support

Visible skin disease can affect self‑esteem. Consider joining support groups (e.g., National Psoriasis Foundation, Autoimmune Skin Disease Association) and seeking counseling if anxiety or depression develops.

Follow‑Up Schedule

• Initial follow‑up: 2–4 weeks after starting systemic therapy.
• Stable disease: every 3–6 months, or sooner if new lesions appear.

Prevention

Because LPP is autoimmune, absolute prevention is impossible, but risk can be reduced:

• Avoid known medication triggers—inform all healthcare providers of your LPP diagnosis before new drugs are prescribed.
• Protect skin from trauma—use padded footwear, avoid tight wristbands, and handle sharp objects carefully.
• Screen for hepatitis C and treat if positive; antiviral therapy can lessen LP activity.
• Limit ultraviolet overexposure—use sunscreen SPF 30+ on exposed skin, even on cloudy days.
• Maintain a healthy immune system—balanced diet, regular exercise, adequate sleep, and smoking cessation.

Complications

If inadequately treated, LPP may lead to:

• Secondary infection of erosions or bullae (cellulitis, impetigo) – requires antibiotics.
• Scarring and post‑inflammatory hyperpigmentation, especially on the face and hands.
• Chronic pruritus causing sleep disturbance and reduced quality of life.
• Linear IgA disease overlap – rare but reported; may need different immunomodulatory therapy.
• Potential progression to bullous pemphigoid if blistering becomes predominant.

When to Seek Emergency Care

---

Sources: Mayo Clinic. Lichen planus pemphigoides. 2022; mayoclinic.org.
National Institutes of Health (NIH). Autoimmune blistering diseases. 2023; nih.gov.
Centers for Disease Control and Prevention (CDC). Hepatitis C and skin disease. 2021; cdc.gov.
JAMA Dermatology. Rituximab in refractory lichen planus pemphigoides: case series. 2021.
Cleveland Clinic. Management of bullous pemphigoid and related disorders. 2022.

```